All-trans retinoic acid (ATRA) is well established as differentiation therapy for acute promyelocytic leukemia (APL) in which the PMLRARa (promyelocytic leukemia-retinoic acid receptor a) fusion protein causes blockade of the retinoic acid (RA) pathway; however, in types of acute myeloid leukemia (AML) other than APL, the mechanism of RA pathway inactivation is not fully understood. This study revealed the potential mechanism of high ATRA sensitivity of mixed-lineage leukemia (MLL)-AF9-positive AML compared with MLL-AF4/5q31-positive AML. Treatment with ATRA induced significant myeloid differentiation accompanied by upregulation of RARa, C/EBPa, C/EBPe and PU.1 in MLL-AF9-positive but not in MLL-AF4/5q31-positive cells. Combining ATRA with cytarabine had a synergistic antileukemic effect in MLL-AF9-positive cells in vitro. The level of dimethyl histone H3 lysine 4 (H3K4me2) in the RARa gene-promoter region, PU.1 upstream regulatory region (URE) and RUNX1 þ 24/ þ 25 intronic enhancer was higher in MLL-AF9-positive cells than in MLL-AF4-positive cells, and inhibiting lysine-specific demethylase 1, which acts as a histone demethylase inhibitor, reactivated ATRA sensitivity in MLL-AF4-positive cells. These findings suggest that the level of H3K4me2 in the RARa genepromoter region, PU.1 URE and RUNX1 intronic enhancer is determined by the MLL-fusion partner. Our findings provide insight into the mechanisms of ATRA sensitivity in AML and novel treatment strategies for ATRA-resistant AML.
INTRODUCTION
Differentiation therapy using all-trans retinoic acid (ATRA) is well established for the treatment of acute promyelocytic leukemia (APL) 1, 2 in which the PML-RARa (promyelocytic leukemia-retinoic acid receptor a) fusion protein causes blockade of the retinoic acid (RA) pathway. 3, 4 There has been significant success using ATRA to treat APL, but there has been little research into the use of ATRA in a non-APL acute myeloid leukemia (AML) setting. In addition, ATRA does not induce myeloid differentiation in non-APL AML cells. Myeloid differentiation is regulated via the activation of RARa gene by ATRA. 4, 5 Studies of the molecular mechanism blocking differentiation in non-APL AML cells indicate that expression of RARa is diminished in non-APL AML cells and that its restoration can induce differentiation of human AML cells. 6, 7 These observations suggest that a lack of RARa expression impairs the RA pathway in non-APL AML cells, blocking myeloid differentiation. In addition, these studies also revealed that epigenetic mechanisms, including DNA methylation, histone methylation and acetylation, are involved in the repression of RARa expression in non-APL AML cells. 6, 7 Based on these findings, recent studies have focused on the development of differentiation therapies for non-APL AML using ATRA combined with epigenetic modifiers. [8] [9] [10] [11] [12] Recently, it has been reported that inhibition of lysine-specific demethylase 1 (LSD1), which demethylates dimethyl histone 3 lysine 4 (H3K4me2) to silence expression of its target gene, reactivates the RA pathway in non-APL AML. 13, 14 Rearrangements of the mixed-lineage leukemia (MLL) gene, which lies on chromosome 11, can involve any of the 79 potential translocation partner genes. 15 MLL-rearranged leukemia is a heterogeneous group, and clinical outcome depends on the translocation partner gene involved. 16, 17 AML patients with t(9;11) and t (11;19) translocations are classified as intermediate risk, while those with all other MLL-fusion partners are classified as high risk. 18 In addition, patients with MLL-rearranged AML grouped according to the translocation partner gene involved can be further stratified by the gene expression signature and promoter methylation pattern of their leukemic cells. 19, 20 In terms of induction of myeloid differentiation in MLL-rearranged AML, we have previously described that the demethylating agent 5-aza-2'-deoxycitidine enhanced the sensitivity of MLL-AF9-expressing AML cells to ATRA, 8 and Iijima et al. 9 have also reported that the combination of the histone deacetylase inhibitor trichostatin A and ATRA was effective as a growth inhibitor and differentiation enhancer in MLL-AF9-expressing leukemia cells. In addition, Niitsu et al. 21 demonstrated that ATRA sensitivity of MLL-rearranged AML cells were varied and that might be related to p16 expression level. These findings suggest that chromatin remodeling, such as histone modification by methylation or acetylation, is an important factor for ATRA sensitivity in MLL-rearranged AML, and the epigenetic priming of RA pathway is necessary for the differentiation therapy in MLL-rearranged AML.
Herein, to determine whether the different partner gene translocations of MLL-rearranged AML affect the sensitivity of ATRA, we investigated the relationship between the level of H3K4me2 in the RARa gene-promoter region, PU.1 gene upstream regulatory region (URE) and RUNX1 gene intronic enhancer and sensitivity to ATRA, and whether, by inhibiting H3K4me2 demethylation in ATRA-resistant cells, sensitivity could be induced in MLL-rearranged human AML cells and murine immortalized cells expressing MLL-AF9 or MLL-AF5q31.
MATERIALS AND METHODS

Cell lines and culture
Human AML cell lines, THP-1 (American Type Culture Collection, Manassas, VA, USA) and MOLM-13 (kindly provided by Dr Bert A. van der Reijden, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands) bearing the MLL-AF9 gene fusion and KOCL-48 (kindly provided by Dr Kanji Sugita, Yamanashi University, Kofu, Japan) bearing MLL-AF4 were cultured in suspension in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (10 mg/ml) at 37 1C in a 5% CO 2 humidified atmosphere.
Reagents ATRA (Sigma-Aldrich, St. Louis, MO, USA), dissolved in dimethyl sulfoxide, and cytarabine (Sigma-Aldrich), dissolved in water, were stored as 1 mM stock solutions in small aliquots at À 20 1C. Tranylcypromine (TCP), a nonreversible LSD1 inhibitor purchased from Sigma-Aldrich, was prepared as a 10 mM stock solution in dissolved dimethyl sulfoxide and stored at À 20 1C.
Retroviral constructs and transduction of Lin
À murine hematopoietic progenitors Retroviral constructs encoding either human MLL-AF9 or MLL-AF5q31 fusion genes were used to establish murine cell lines expressing MLL-AF9 or MLL-AF5q31 fusion proteins as described previously. 8 Clinical AML cell samples Primary leukemic cells expressing the MLL-AF9 fusion were obtained from the diagnostic bone marrow samples of two pediatric AML patients following informed parental consent, in accordance with the revised Helsinki protocol. The AML cells were purified from bone marrow as mononuclear cells using Ficoll density-gradient centrifugation and stored in liquid nitrogen. On thawing, cells were plated in methylcellulose medium (MethoCult H4434, Stem Cell Technologies, Vancouver, BC, Canada) at 1.0 Â 10 6 /ml and cultured with ATRA (1 mM).
Morphological studies
Cells at 1.0 Â 10 6 /ml were cultured with ATRA (1 mM) and/or TCP (10 mM) for 3 days. Cytospin preparations were stained with May-Grü nwald Giemsa.
Nitroblue tetrazolium (NBT) reduction test for detection of myeloid differentiation
After culture with ATRA (1 mM) and/or TCP (10 mM) for 3 days, cells were subjected to a NBT reduction test using the NBT Reduction Kit (SigmaAldrich) according to the manufacturer's instructions. The percentage of cells containing the precipitated formazan particles was determined by light microscopy. At least 200 cells were counted per sample.
Cytotoxicity assay ATRA, TCP and cytarabine cytotoxicity were measured by cell viability using a WST assay (Cell Count Reagent SF, Nacalai Tesque Inc., Kyoto, Japan). The concentration of each drug causing 50% growth inhibition (IC50) was determined. The effect of ATRA and cytarabine and of ATRA and TCP cytotoxic interactions were determined from the combination index (CI); CIo1, CI ¼ 1 and CI41 indicate a synergistic, an additive and an antagonistic effect, respectively. The CI was calculated using the following equation: Cell-cycle analysis Cells were harvested, washed twice with PBS and incubated for 30 min with propidium iodide (PI) to stain DNA. Propidium iodide fluorescence was analyzed using a FACS Calibur, and the cell-cycle phase was determined on the basis of DNA content using the ModFit LT software (Verity Software House, http://www.vsh.com/).
Real-time reverse transcriptase-PCR (RT-PCR)
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Venio, The Netherlands) according to the manufacturer's instructions. The SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) was used to synthesize cDNA according to the manufacturer's instructions, and real-time RT-PCR was performed using the 7500 Real-time PCR System (Applied Biosystems, Foster City, CA, USA) with SYBR Green 1 Master Mix (Takara Bio, Tokyo, Japan). Relative expression of target mRNA was determined using the comparative threshold (DCt) method. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. The primer pairs used in this study are listed in Supplementary Table S1 . A standard curve analysis with stepwise sample dilution demonstrated that all primer pairs had similar efficiency (data not shown).
Immunoblot analysis
Immunoblot analysis was performed as described previously. 22 The following primary antibodies were used: anti-RARa (diluted 1:200), anti-C/EBPa (diluted 1:750), anti-C/EBPe (diluted 1:200) and anti-PU.1 (diluted 1:500). All antibodies were purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out using the Simple ChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology Inc., Danvers, MA, USA) according to the manufacturer's instructions. IP was performed with the following antibodies: anti-H3K4me2 (Abcam, Tokyo, Japan) and anti-histone H3 (Cell Signaling Technology Inc.). IP DNA in each IP sample of human cell lines was analyzed by quantitative RT-PCR using RARa gene-specific primers covering the promoter and 5 0 untranslated region (5 0 UTR): from À 1000 to þ 1000 bp from the transcriptional start site, 23, 24 PU.1 URE 25 and RUNX1 þ 24/ þ 25 intronic enhancer. 26 Also, IP DNA in each IP sample of murine cell lines was analyzed by quantitative RT-PCR using Rara genespecific primers covering the promoter and 5 0 UTR:from À 1000 to þ 1000 bp from the transcriptional start site, Sfpi.1 URE and Runx1 þ 24/ þ 25 intronic enhancer. 25, 26 The list of primer sequences are shown in Supplementary Tables 2 and 3. All expression values were normalized against histone H3.
Statistical analysis
Statistical analysis was performed using the Student's t-test. A P-valueo0.05 was considered statistically significant.
RESULTS
ATRA induces myeloid differentiation and growth inhibition with cell-cycle arrest in human MLL-AF9-positive AML cells First, we evaluated whether ATRA could induce myeloid differentiation, as observed in APL, in three human AML cell lines with MLL rearrangements. ATRA induced morphological changes, such as irregularly shaped nuclei, extended cytoplasm and the appearance of fine granules, more markedly in THP-1 and MOLM-13 cell lines, which bear the MLL-AF9 fusion gene, than in KOCL-48 which bears MLL-AF4 (Figure 1a ). These morphological changes corresponded with a reduction in NBT, which indicated an increase in mature myeloid cell function (for example, phagocytosis activity), and the induction of CD11b on flow cytometric analysis (Figures 1b and c) . Figure 1d ). Taken together, these data demonstrate that the effects of ATRA on the induction of myeloid differentiation were more apparent, and that the effects of ATRA on growth inhibition were significantly greater, on the MLL-AF9-positive AML cell line than on the MLL-AF4-positive cell line. These data were consistent with the previous studies showing MLL-AF9-positive AML cell line was sensitive to ATRA. 8, 9 The RA pathway is more profoundly impaired in human MLL-AF4-positive cells than in MLL-AF9-positive cells The expression of RARa, C/EBPa, C/EBPe and PU.1 genes is modulated in myeloid differentiation by RA. Using western blotting analysis, we found that RARa and C/EBPe expression levels, which are directly regulated by ATRA, were increased in response to ATRA in the MLL-AF9-positive cell lines THP-1 and MOLM-13 but not in the MLL-AF4-positive cell line KOCL-48. In addition, expression of C/EBPa and PU.1, which are important transcriptional factors in myeloid differentiation, was also increased only in MLL-AF9-positive cells (Figure 1e ).
The effect of ATRA on primary MLL-AF9-positive AML cells To confirm these effects of ATRA on myeloid differentiation, we evaluated the expression levels of RARa, C/EBPa, C/EBPe and PU.1 in two primary AML samples bearing MLL-AF9 fusion using realtime RT-PCR analysis. In accordance with the results of the western blotting analysis of human MLL-AF9-positive AML cell lines, the expression levels of RARa, C/EBPa, C/EBPe and PU.1 were upregulated in both primary MLL-AF9-positive AML samples (Supplementary Figure S2) . Collectively, these results showed clearly that ATRA was able to induce myeloid differentiation and activate the RA pathway in MLL-AF9-positive AML cells. In contrast, ATRA did not induce myeloid differentiation or activate the RA pathway in MLL-AF4-positive cells.
The effect of ATRA on murine MLL-rearranged immortalized cells To confirm that the particular MLL-fusion partner (AF9 or AF4) directly determined the activity of the RA pathway, our aim was to generate immortalized murine cells expressing MLL-AF9 or MLL-AF4; however, we were unable to transform murine hematopoietic progenitor cells using MLL-AF4. Therefore AF5q31, a member of the AF4 family of genes, fused with MLL was used as an alternative. 8 Similar to the results of the experiments with human AML cells, ATRA induced morphological changes only in the murine MLL-AF9-expressing cells (Figure 2a ), and these changes were accompanied by a reduction in NBT and upregulation of Mac 1expression (Figures 2b and c) . In addition to these effects, the percentage of cells in G0/G1 was greater among the MLL-AF9-expressing cells (Supplementary Figure S1b) , and the ATRA IC50 was much lower for MLL-AF9-expressing cells than for MLL-AF5q31-expressing cells (2.01±0.39 vs 32.6±14.5 mM; Figure 2d ). The expression levels of Rara, C/ebpa, C/ebpe and Sfpi.1 determined by real-time RT-PCR were significantly upregulated in response to ATRA in the MLL-AF9-expressing cells but were unchanged in the MLL-AF5q31-expressing cells (Figure 2e ), suggesting that murine Lin À hematopoietic progenitor cells expressing MLL-AF9, but not those expressing MLL-AF5q31, remain sensitive to ATRA. Thus, it could be concluded that particular MLL-fusion partners affect sensitivity to ATRA.
A synergistic antileukemic effect between cytarabine and ATRA in MLL-AF9-positive AML cells To explore the possibility of a synergistic antileukemic effect between ATRA and cytarabine, one of the major drugs used to (Figures 3a and b) . ATRA in combination with cytarabine was, therefore, more effective than cytarabine alone for ablating MLL-AF9-positive cells in vitro.
ChIP assays of H3K4me2 on MLL-rearranged human AML cell lines and murine MLL-rearranged immortalized cells Next, we carried out ChIP assays on MLL-rearranged human AML cell lines to investigate whether inactivation of the RA pathway was correlated with decreased H3K4me2 in the RARa-promoter region, which contained the RA response elements. 23 IP DNA was analyzed using RARa gene-specific primers mapping to the promoter and 5 0 UTR from À 1000 to þ 1000 bp from the transcriptional start site. The levels of H3K4me2 normalized against histone H3 were lower in the MLL-AF4-positive cell line, KOCL-48, than in the MLL-AF9-positive cell lines, THP-1 and MOLM-13. These findings revealed that ATRA sensitivity correlates with the H3K4me2 level in the RARa gene in MLL-rearranged AML cell lines (Figure 4a ). In addition, we evaluated the histone modification status at the PU.1 proximal and distal URE and RUNX1 þ 24/ þ 25 intronic enhancer, which were also associated with myeloid differentiation. 25, 26 The levels of H3K4me2 at these regions were lower in the MLL-AF4-positive cell line, KOCL-48, than in the MLL-AF9-positive cell lines, THP-1 and MOLM-13 ( Figure 4b) . Collectively, MLL-AF9-positive cell lines bear higher H3K4me2 level in the RARa gene, PU.1 URE and RUNX1 intronic enhancer than MLL-AF4 positive cell line, resulting in efficient induction of myeloid differentiation in MLL-AF9-positive cell lines by ATRA.
To confirm the particular MLL-fusion partner (AF9 or AF4) directly modified the histone modification, such as the H3K4me2 level, we investigated the levels of H3K4me2 at Rara genepromoter, Sfpi.1 URE, and Runx1 intronic enhancer in immortalized murine cells expressing MLL-AF9 or MLL-AF5q31. Consistent with the result of human AML cell lines, the levels of H3K4me2 normalized against histone H3 were lower in the murine cells expressing MLL-AF5q31 than in the murine cells expressing MLL-AF9 at Rara gene-promoter, Sfpi.1 URE, and Runx1 intronic enhancer (Figures 4c and d) . (Figures 5a and b) . Furthermore, ATRA/TCP induced higher-intensity expression of CD11b and increased the proportion in G0/G1 cellcycle arrest (Figure 5c and Supplementary Figure S1c) . Western blotting analysis revealed that the expression of RARa, C/EBPa, C/EBPe and PU.1 increased in response to ATRA/TCP (Figure 5d ), suggesting that the combination of ATRA and TCP reactivates the RA pathway. We therefore treated KOCL-48 cells with a titrating dose of ATRA with 10 mM TCP or without TCP. The ATRA IC50 was significantly decreased when added in combination with TCP, and the CI showed that ATRA and TCP had a synergistic effect (Figure 5e , ATRA IC50 of 72.2 ± 7.95 mM without TCP vs 12.9 ± 3.04 mM with TCP). Finally, we tested whether TCP could upregulate the level of H3K4me2 in the RARa gene-promoter region and 5 0 UTR. The levels of H3K4me2 in the presence of TCP were increased in a dosedependent manner (Figure 5f) . Similarly, the level of H3K4me2 in the PU.1 URE and RUNX1 intronic enhancer were also upregulated in the presence of TCP (Figure 5g ). These findings suggest that inactivation of the RA pathway and myeloid differentiation block are induced by a decrease in the level of H3K4me2 in the RARa gene-promoter, the PU.1 URE and RUNX1 intronic enhancer.
DISCUSSION
In this study, we have examined the mechanisms of ATRA sensitivity in non-APL AML cells. We found that MLL-AF9-positive cells were sensitive to ATRA and that this was accompanied by the upregulation of myeloid differentiation genes, such as C/EBPa, [27] [28] [29] C/EBPe 30-32 and PU.1. 33, 34 In contrast, MLL-AF4/AF5q31-positive cells were not sensitive to ATRA, suggesting that the RA pathway is more strongly inactivated in MLL-AF4/AF5q31-positive cells than in MLL-AF9-positive cells. In addition, the experiments on murine MLL-rearranged immortalized cells revealed that the response to ATRA was dependent on the MLL-fusion partner gene.
Furthermore, we demonstrated a synergistic antileukemic effect between cytarabine and ATRA in MLL-AF9-positive cells, which were sensitive to ATRA, in vitro. Previous studies have shown that ATRA induces cell-cycle arrest and apoptosis in nucleophosmin 1 (NPM1)-mutated AML cells and that the NPM1 mutation sensitizes the AML cells to ATRA and cytarabine in vitro. 35, 36 However, several subsequent studies have failed to reveal any clinical benefit of combining ATRA with conventional chemotherapy. [37] [38] [39] Thus it will be important to determine whether the synergistic antileukemic effect of cytarabine and ATRA seen in MLL-AF9-positive AML cells in vitro is corroborated in vivo.
We also demonstrated that the level of H3K4me2 in the RARa gene-promoter region was closely associated with ATRA sensitivity. Our results showed that loss of H3K4me2 levels in RARa resulted in the inactivation of the RA pathway and that inhibition of LSD1 could reactivate the RA pathway in ATRA-resistant MLL-AF4-positive cells. In addition, we revealed that the levels of H3K4me2 in the PU.1 URE and RUNX1 intronic enhancer were also associated with the degree of ATRA-mediated myeloid differentiation, which was restored by the inhibition of LSD1.
Recent studies demonstrated that MLL was directly bound to RUNX1 physically and functionally. 40, 41 Also, RUNX1 bound to the PU.1 URE, which has enhancer and repressor activity to regulate PU.1 expression. 24, 42 Furthermore, RUNX1 þ 24/ þ 25 intronic enhancer was identified as a cis-regulatory element of RUNX1 gene expression in hematopoietic stem cells. 25 Collectively, MLL, RUNX1 and PU.1 were closely interacted, and these interactions were modified by epigenetic regulation at the gene regulatory region, such as PU.1 URE or RUNX1 intronic enhancer, suggesting MLL fusions might interfere the myeloid differentiation caused by RUNX1 and PU.1 in different manner. Epigenetic research in leukemia is a rapidly developing field 43 and in APL the PML-RARa fusion gene is now known to recruit various histone-modifying enzymes. Binding of the large PML-RARa fusion-protein complex to the promoter of the RARa target gene 'closes' the chromatin structure, resulting in the repression of gene expression, blocking the RA pathway, and thereby allowing oncogenic programs to progress. 44, 45 Similarly, the AML1-ETO fusion protein (produced by the t(8;21) translocation) also recruits histone deacetylase and DNA methyltransferase, which block the RA pathway and promote H3K4me2 in RARa and sensitivity to ATRA in AML K Sakamoto et al leukomogenesis. 46, 47 In addition, the demethylating agent or histone deacetylase inhibitor enhance the ATRA-mediated myeloid differentiation in MLL-AF9-expressing AML cells. 8, 9 These observations suggest that epigenetic modification is an important factor for leukomogenesis in some AML subtypes, including MLLrearranged AML.
LSD1, which demethylates histone H3 at lysine 4 (H3K4) and lysine 9 (H3K9), was the first histone demethylase to be identified. 48 LSD1 is overexpressed in various cancers, and recent researches showed that this epigenetic modifier is associated with the development of drug resistance. 49, 50 Schenk et al. 13 reported that the LSD1 inhibitor TCP can reactivate ATRA sensitivity in the ATRA-resistant TEX cell line in vitro and diminish the engraftment of primary AML samples in vivo. In addition, they demonstrated that the combination of ATRA and TCP led to upregulation of gene expression associated with the myeloid differentiation program and apoptosis, accompanied by increased amounts of H3K4me2 near the transcriptional start sites. 13 Similarly, in the current study we found that the amount of H3K4me2 in the region from À 1000 to þ 1000 from the transcriptional start site of RARa was correlated with ATRA sensitivity and that TCP could reactivate ATRA sensitivity in an ATRA-resistant cell line expressing the MLL-AF4 fusion protein. We also revealed that TCP restored the levels of H3K4me2 in the PU.1 URE and RUNX1 intronic enhancer in the ATRA-resistant cell line. The IC50 of ATRA in combination with TCP was, however, much higher than the pharmacological concentration of ATRA for clinical use, suggesting that a more potent inhibitor of histone demethylase is required for reactivation of ATRA sensitivity in an ATRA-resistant cell. [51] [52] [53] In conclusion, we found that MLL-AF9-positive AML cells were sensitive to ATRA and that a high level of H3K4me2 in the promoter region of the RARa gene, PU.1 URE and RUNX1 intronic enhancer is associated with ATRA sensitivity in this subtype. Addition of ATRA to cytarabine had a synergistic antileukemic effect on MLL-AF9-positive AML cells in vitro, suggesting that in cases of AML with high levels of H3K4me2 in the RARa promoter region, PU.1 URE and RUNX1 intronic enhancer, ATRA would be able to sensitize leukemic cells to cytarabine; an in vivo study is now required to confirm this. Furthermore, our findings indicate that epigenetic modifiers, such as LSD1 inhibitors, are potentially useful for treating ATRA-resistant AML, including MLL-rearranged AML. H3K4me2 in RARa and sensitivity to ATRA in AML K Sakamoto et al
